Analgesics
Antiandrogens
Azvudine
Bromhexine
Budesonide
Colchicine
Conv. Plasma
Curcumin
Famotidine
Favipiravir
Fluvoxamine
Hydroxychlor..
Ivermectin
Lifestyle
Melatonin
Metformin
Minerals
Molnupiravir
Monoclonals
Naso/orophar..
Nigella Sativa
Nitazoxanide
Paxlovid
Quercetin
Remdesivir
Thermotherapy
Vitamins
More

Other
Feedback
Home
Top
Results
Abstract
All antiandrogen studies
Meta analysis
 
Feedback
Home
next
study
previous
study
c19early.org COVID-19 treatment researchAntiandrogenAntiandrogens (more..)
Melatonin Meta
Metformin Meta
Azvudine Meta
Bromhexine Meta Molnupiravir Meta
Budesonide Meta
Colchicine Meta
Conv. Plasma Meta Nigella Sativa Meta
Curcumin Meta Nitazoxanide Meta
Famotidine Meta Paxlovid Meta
Favipiravir Meta Quercetin Meta
Fluvoxamine Meta Remdesivir Meta
Hydroxychlor.. Meta Thermotherapy Meta
Ivermectin Meta

All Studies   Meta Analysis    Recent:   

Proxalutamide Significantly Accelerates Viral Clearance and Reduces Time to Clinical Remission in Patients with Mild to Moderate COVID-19: Results from a Randomized, Double-Blinded, Placebo-Controlled Trial

Cadegiani et al., Cureus, doi:10.7759/cureus.13492
Feb 2021  
  Post
  Facebook
Share
  Source   PDF   All Studies   Meta AnalysisMeta
Viral clearance 92% Improvement Relative Risk Recovery 77% Recovery time 85% no CI Recovery time (b) 81% no CI Proxalutamide  Cadegiani et al.  EARLY TREATMENT  DB RCT Is early treatment with antiandrogens beneficial for COVID-19? Double-blind RCT 237 patients in Brazil Improved viral clearance (p<0.0001) and recovery (p<0.0001) c19early.org Cadegiani et al., Cureus, February 2021 Favorsproxalutamide Favorscontrol 0 0.5 1 1.5 2+
7th treatment shown to reduce risk in September 2020
 
*, now with p = 0.000000056 from 49 studies.
No treatment is 100% effective. Protocols combine treatments. * >10% efficacy, ≥3 studies.
4,300+ studies for 75 treatments. c19early.org
RCT 234 mild-moderate COVID-19 patients with 171 treated with proxalutamide, showing significantly faster viral clearance and recovery. Third party analysis suggests potential randomization failure:1.
This study is excluded in meta analysis: potential randomization failure.
risk of no viral clearance, 92.1% lower, RR 0.08, p < 0.001, treatment 7 of 171 (4.1%), control 34 of 66 (51.5%), NNT 2.1, day 7, not including loss of taste or smell.
risk of no recovery, 76.8% lower, RR 0.23, p < 0.001, treatment 30 of 171 (17.5%), control 50 of 66 (75.8%), NNT 1.7, day 7, including loss of taste or smell.
recovery time, 85.0% lower, relative time 0.15, treatment 171, control 66, day 7, not including loss of taste or smell.
recovery time, 80.7% lower, relative time 0.19, treatment 171, control 66, day 7, including loss of taste or smell.
Effect extraction follows pre-specified rules prioritizing more serious outcomes. Submit updates
Cadegiani et al., 22 Feb 2021, Double Blind Randomized Controlled Trial, Brazil, peer-reviewed, 8 authors, average treatment delay 4.2 days.
This PaperAntiandrogensAll
Proxalutamide Significantly Accelerates Viral Clearance and Reduces Time to Clinical Remission in Patients with Mild to Moderate COVID-19: Results from a Randomized, Double-Blinded, Placebo-Controlled Trial
Flavio A Cadegiani, John Mccoy, Carlos Gustavo Wambier, Sergio Vaño-Galván, Jerry Shapiro, Antonella Tosti, Ricardo A Zimerman, Andy Goren
Cureus, doi:10.7759/cureus.13492
Background The entry of severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) into type II pneumocytes is dependent on a modification of viral spike proteins by transmembrane protease serine 2 (TMPRSS2) expressed on the surface of human cells. TMPRSS2 is regulated by the androgen receptor, hence, SARS-CoV-2 infectivity is indirectly dependent on androgenic status and phenotype. Previously, we have reported that men affected by androgenetic alopecia (AGA) are overrepresented in severe coronavirus disease 2019 . Additionally, we have reported that men taking antiandrogenic drugs, e.g., 5-alpha-reductase inhibitors (5ARis), are less likely to have severe COVID-19. Here we aimed to test whether the androgen receptor antagonist, Proxalutamide, would be a beneficial treatment for subjects with SARS-CoV-2 infection. Methods Male and female subjects were recruited to a double-blinded, randomized, prospective, investigational study of Proxalutamide for the treatment of COVID-19. Mild to moderate, non-hospitalized subjects, who were confirmed positive for SARS-CoV-2, were treated with either Proxalutamide 200 mg/day or placebo. Endpoints for the study were remission time (days) and the percentage of subjects confirmed negative for SARS-CoV-2 on Day 7 after treatment. A negative SARS-CoV-2 test was defined by concentration-time (Ct)>40 determined by real-time reverse transcription-polymerase chain reaction (rtPCR). Results Two-hundred thirty-six (2360 subjects were included in the study (108 female, 128 male); 171 were randomized to the Proxalutamide arm and 65 were in the placebo group. On Day 7, SARS-CoV-2 became non-detectable with rtPCR (cT>40) in 82% of the subjects in the Proxalutamide group versus 31% in the placebo group (p < 0.001). The average clinical remission time for patients treated with Proxalutamide was 4.2 ±5.4 days versus 21.8 ±13.0 days in the placebo arm (p < 0.001). Conclusion Proxalutamide significantly accelerated viral clearance on Day 7 in mild to moderate COVID-19 patients versus placebo. Further, the time to clinical remission was significantly reduced in patients treated with Proxalutamide versus placebo.
Additional Information In compliance with the ICMJE uniform disclosure form, all authors declare the following: Payment/services info: All authors have declared that no financial support was received from any organization for the submitted work. Financial relationships: All authors have declared that they have no financial relationships at present or within the previous three years with any organizations that might have an interest in the submitted work. Other relationships: All authors have declared that there are no other relationships or activities that could appear to have influenced the submitted work.
References
Cadegiani, Lim, Goren, Clinical symptoms of hyperandrogenic women diagnosed with COVID-19, J Eur Acad Dermatol Venereol, doi:10.1111/jdv.17004
Goren, Vaño-Galván, Wambier, A preliminary observation: male pattern hair loss among hospitalized COVID-19 patients in Spain -a potential clue to the role of androgens in COVID-19 severity, J Cosmet Dermatol, doi:10.1111/jocd.13443
Goren, Wambier, Herrera, Anti-androgens may protect against severe COVID-19 outcomes: results from a prospective cohort study of 77 hospitalized men, J Eur Acad Dermatol Venereol, doi:10.1111/jdv.16953.10.1111/jdv.16953
Hoffmann, Kleine-Weber, Schroeder, SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a clinically proven protease inhibitor, Cell, doi:10.1016/j.cell.2020.02.052
Lucas, Heinlein, Kim, The androgen-regulated protease TMPRSS2 activates a proteolytic cascade involving components of the tumor microenvironment and promotes prostate cancer metastasis, Cancer Discov, doi:10.1158/2159-8290.CD-13-1010
Mallett, Allen, Graziadio, At what times during infection is SARS-CoV-2 detectable and no longer detectable using RT-PCR-based tests? A systematic review of individual participant data, BMC Med, doi:10.1186/s12916-020-01810-8
Mccoy, Cadegiani, Wambier, 5-alpha-reductase inhibitors are associated with reduced frequency of COVID-19 symptoms in males with androgenetic alopecia, J Eur Acad Dermatol Venereol, doi:10.1111/jdv.17021
Mccoy, Wambier, Herrera, Androgen receptor genetic variant predicts COVID-19 disease severity: a prospective longitudinal study of hospitalized COVID-19 male patients, J Eur Acad Dermatol Venereol, doi:10.1111/jdv.16956
Qu, Gu, Wang, Metabolomic profiling to evaluate the efficacy of Proxalutamide, a novel androgen receptor antagonist, in prostate cancer cells, Invest New Drugs
Ravikirti, Pattadar, Ivermectin as a potential treatment for mild to moderate COVID-19 -a double blind randomized placebo-controlled trial, PREPRINT, doi:10.1101/2021.01.05.21249310
Rocco, Silva, Cruz, Early use of nitazoxanide in mild Covid-19 disease: randomised, placebo-controlled trial, Eur Resp J Jan, doi:10.1183/13993003.03725-2020
Wambier, Vaño-Galván, Mccoy, Androgenetic alopecia present in the majority of hospitalized COVID-19 patients -the "Gabrin sign, J Am Acad Dermatol, doi:10.1016/j.jaad.2020.05.079
Wambier, Vaño-Galván, Mccoy, Pai, Dhurat et al., Androgenetic alopecia in COVID-19: compared to age-matched epidemiologic studies and hospital outcomes with or without the Gabrin sign, J Am Acad Dermatol, doi:10.1016/j.jaad.2020.07.099
Zhou, Xu, Zhang, Preclinical profile and phase I clinical trial of a novel androgen receptor antagonist GT0918 in castration-resistant prostate cancer, Eur J Cancer, doi:10.1016/j.ejca.2020.04.013
{ 'indexed': {'date-parts': [[2024, 4, 3]], 'date-time': '2024-04-03T14:39:25Z', 'timestamp': 1712155165593}, 'reference-count': 14, 'publisher': 'Springer Science and Business Media LLC', 'content-domain': {'domain': [], 'crossmark-restriction': False}, 'published-print': {'date-parts': [[2021, 2, 22]]}, 'DOI': '10.7759/cureus.13492', 'type': 'journal-article', 'created': {'date-parts': [[2021, 2, 22]], 'date-time': '2021-02-22T17:37:11Z', 'timestamp': 1614015431000}, 'source': 'Crossref', 'is-referenced-by-count': 24, 'title': 'Proxalutamide Significantly Accelerates Viral Clearance and Reduces Time to Clinical Remission ' 'in Patients with Mild to Moderate COVID-19: Results from a Randomized, Double-Blinded, ' 'Placebo-Controlled Trial', 'prefix': '10.7759', 'author': [ {'given': 'Flavio A', 'family': 'Cadegiani', 'sequence': 'first', 'affiliation': []}, {'given': 'John', 'family': 'McCoy', 'sequence': 'additional', 'affiliation': []}, {'given': 'Carlos', 'family': 'Gustavo Wambier', 'sequence': 'additional', 'affiliation': []}, {'given': 'Sergio', 'family': 'Vaño-Galván', 'sequence': 'additional', 'affiliation': []}, {'given': 'Jerry', 'family': 'Shapiro', 'sequence': 'additional', 'affiliation': []}, {'given': 'Antonella', 'family': 'Tosti', 'sequence': 'additional', 'affiliation': []}, {'given': 'Ricardo A', 'family': 'Zimerman', 'sequence': 'additional', 'affiliation': []}, {'given': 'Andy', 'family': 'Goren', 'sequence': 'additional', 'affiliation': []}], 'member': '297', 'reference': [ { 'key': 'ref1', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.cell.2020.02.052', 'article-title': 'SARS-CoV-2 cell entry depends on ACE2 and TMPRSS2 and is blocked by a ' 'clinically proven protease inhibitor', 'volume': '181', 'author': 'Hoffmann M', 'year': '2020', 'unstructured': 'Hoffmann M, Kleine-Weber H, Schroeder S, et al.. SARS-CoV-2 cell entry ' 'depends on ACE2 and TMPRSS2 and is blocked by a clinically proven ' 'protease inhibitor. Cell. 2020, 181:271-280. 10.1016/j.cell.2020.02.052', 'journal-title': 'Cell'}, { 'key': 'ref2', 'doi-asserted-by': 'publisher', 'DOI': '10.1158/2159-8290.CD-13-1010', 'article-title': 'The androgen-regulated protease TMPRSS2 activates a proteolytic cascade ' 'involving components of the tumor microenvironment and promotes ' 'prostate cancer metastasis', 'volume': '4', 'author': 'Lucas JM', 'year': '2014', 'unstructured': 'Lucas JM, Heinlein C, Kim T, et al.. The androgen-regulated protease ' 'TMPRSS2 activates a proteolytic cascade involving components of the ' 'tumor microenvironment and promotes prostate cancer metastasis. Cancer ' 'Discov. 2014, 4:1310-1325. 10.1158/2159-8290.CD-13-1010', 'journal-title': 'Cancer Discov'}, { 'key': 'ref3', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.jaad.2020.05.079', 'article-title': 'Androgenetic alopecia present in the majority of hospitalized COVID-19 ' 'patients - the "Gabrin sign"', 'volume': '83', 'author': 'Wambier CG', 'year': '2020', 'unstructured': 'Wambier CG, Vaño-Galván S, McCoy J, et al.. Androgenetic alopecia ' 'present in the majority of hospitalized COVID-19 patients - the "Gabrin ' 'sign". J Am Acad Dermatol. 2020, 83:680-682. 10.1016/j.jaad.2020.05.079', 'journal-title': 'J Am Acad Dermatol'}, { 'key': 'ref4', 'doi-asserted-by': 'publisher', 'DOI': '10.1111/jocd.13443', 'article-title': 'A preliminary observation: male pattern hair loss among hospitalized ' 'COVID-19 patients in Spain - a potential clue to the role of androgens ' 'in COVID-19 severity', 'volume': '19', 'author': 'Goren A', 'year': '2020', 'unstructured': 'Goren A, Vaño-Galván S, Wambier CG, et al.. A preliminary observation: ' 'male pattern hair loss among hospitalized COVID-19 patients in Spain - a ' 'potential clue to the role of androgens in COVID-19 severity. J Cosmet ' 'Dermatol. 2020, 19:1545-1547. 10.1111/jocd.13443', 'journal-title': 'J Cosmet Dermatol'}, { 'key': 'ref5', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.jaad.2020.07.099', 'article-title': 'Androgenetic alopecia in COVID- 19: compared to age-matched ' 'epidemiologic studies and hospital outcomes with or without the Gabrin ' 'sign', 'volume': '83', 'author': 'Wambier CG', 'year': '2020', 'unstructured': 'Wambier CG, Vaño-Galván S, McCoy J, Pai S, Dhurat R, Goren A. ' 'Androgenetic alopecia in COVID- 19: compared to age-matched ' 'epidemiologic studies and hospital outcomes with or without the Gabrin ' 'sign. J Am Acad Dermatol. 2020, 83:E453-E454. 10.1016/j.jaad.2020.07.099', 'journal-title': 'J Am Acad Dermatol'}, { 'key': 'ref6', 'doi-asserted-by': 'publisher', 'DOI': '10.1111/jdv.17004', 'article-title': 'Clinical symptoms of hyperandrogenic women diagnosed with COVID-19', 'volume': '35', 'author': 'Cadegiani FA', 'year': '2020', 'unstructured': 'Cadegiani FA, Lim RK, Goren A, et al.. Clinical symptoms of ' 'hyperandrogenic women diagnosed with COVID-19. J Eur Acad Dermatol ' 'Venereol. 2020, 35:e101-e104. 10.1111/jdv.17004', 'journal-title': 'J Eur Acad Dermatol Venereol'}, { 'key': 'ref7', 'doi-asserted-by': 'publisher', 'DOI': '10.1111/jdv.16953. 10.1111/jdv.16953', 'article-title': 'Anti-androgens may protect against severe COVID-19 outcomes: results ' 'from a prospective cohort study of 77 hospitalized men', 'volume': '25', 'author': 'Goren A', 'year': '2020', 'unstructured': 'Goren A, Wambier CG, Herrera S, et al.. Anti-androgens may protect ' 'against severe COVID-19 outcomes: results from a prospective cohort ' 'study of 77 hospitalized men. J Eur Acad Dermatol Venereol. 2020, ' '25:e13-e15. 10.1111/jdv.16953. 10.1111/jdv.16953', 'journal-title': 'J Eur Acad Dermatol Venereol'}, { 'key': 'ref8', 'doi-asserted-by': 'publisher', 'DOI': '10.1111/jdv.17021', 'article-title': '5-alpha-reductase inhibitors are associated with reduced frequency of ' 'COVID-19 symptoms in males with androgenetic alopecia', 'volume': '[Epub ahead of print]', 'author': 'McCoy J', 'year': '2020', 'unstructured': 'McCoy J, Cadegiani FA, Wambier CG, et al.. 5-alpha-reductase inhibitors ' 'are associated with reduced frequency of COVID-19 symptoms in males with ' 'androgenetic alopecia. J Eur Acad Dermatol Venereol. 2020, [Epub ahead ' 'of print]:10.1111/jdv.17021', 'journal-title': 'J Eur Acad Dermatol Venereol'}, { 'key': 'ref9', 'doi-asserted-by': 'publisher', 'DOI': '10.1111/jdv.16956', 'article-title': 'Androgen receptor genetic variant predicts COVID-19 disease severity: a ' 'prospective longitudinal study of hospitalized COVID-19 male patients', 'volume': '25', 'author': 'McCoy J', 'year': '2020', 'unstructured': 'McCoy J, Wambier CG, Herrera S, et al.. Androgen receptor genetic ' 'variant predicts COVID-19 disease severity: a prospective longitudinal ' 'study of hospitalized COVID-19 male patients. J Eur Acad Dermatol ' 'Venereol. 2020 Sep, 25:10.1111/jdv.16956', 'journal-title': 'J Eur Acad Dermatol Venereol'}, { 'key': 'ref10', 'article-title': 'Metabolomic profiling to evaluate the efficacy of Proxalutamide, a ' 'novel androgen receptor antagonist, in prostate cancer cells', 'volume': '38', 'author': 'Qu F', 'year': '2020', 'unstructured': 'Qu F, Gu Y, Wang Q, et al.. Metabolomic profiling to evaluate the ' 'efficacy of Proxalutamide, a novel androgen receptor antagonist, in ' 'prostate cancer cells. Invest New Drugs. 2020, 38:1292-1302.', 'journal-title': 'Invest New Drugs'}, { 'key': 'ref11', 'doi-asserted-by': 'publisher', 'DOI': '10.1016/j.ejca.2020.04.013', 'article-title': 'Preclinical profile and phase I clinical trial of a novel androgen ' 'receptor antagonist GT0918 in castration-resistant prostate cancer', 'volume': '134', 'author': 'Zhou T', 'year': '2020', 'unstructured': 'Zhou T, Xu W, Zhang W, et al.. Preclinical profile and phase I clinical ' 'trial of a novel androgen receptor antagonist GT0918 in ' 'castration-resistant prostate cancer. Eur J Cancer. 2020, 134:29-40. ' '10.1016/j.ejca.2020.04.013', 'journal-title': 'Eur J Cancer'}, { 'key': 'ref12', 'doi-asserted-by': 'publisher', 'DOI': '10.1183/13993003.03725-2020', 'article-title': 'Early use of nitazoxanide in mild Covid-19 disease: randomised, ' 'placebo-controlled trial', 'volume': '2020', 'author': 'Rocco PRM', 'year': '2020', 'unstructured': 'Rocco PRM, Silva PL, Cruz FF, et al.. Early use of nitazoxanide in mild ' 'Covid-19 disease: randomised, placebo-controlled trial. Eur Resp J Jan. ' '2020, 2020:2003725. 10.1183/13993003.03725-2020', 'journal-title': 'Eur Resp J Jan'}, { 'key': 'ref13', 'doi-asserted-by': 'publisher', 'DOI': '10.1186/s12916-020-01810-8', 'article-title': 'At what times during infection is SARS-CoV-2 detectable and no longer ' 'detectable using RT-PCR-based tests? A systematic review of individual ' 'participant data', 'volume': '18', 'author': 'Mallett S', 'year': '2020', 'unstructured': 'Mallett S, Allen AJ, Graziadio S, et al.. At what times during infection ' 'is SARS-CoV-2 detectable and no longer detectable using RT-PCR-based ' 'tests? A systematic review of individual participant data. BMC Med. ' '2020, 18:346. 10.1186/s12916-020-01810-8', 'journal-title': 'BMC Med'}, { 'key': 'ref14', 'doi-asserted-by': 'publisher', 'DOI': '10.1101/2021.01.05.21249310', 'article-title': 'Ivermectin as a potential treatment for mild to moderate COVID-19 - a ' 'double blind randomized placebo-controlled trial [PREPRINT]', 'author': 'Ravikirti', 'year': '2021', 'unstructured': 'Ravikirti, Roy R, Pattadar C, et al.. Ivermectin as a potential ' 'treatment for mild to moderate COVID-19 - a double blind randomized ' 'placebo-controlled trial [PREPRINT]. medRxiv. 2021, ' '10.1101/2021.01.05.21249310', 'journal-title': 'medRxiv'}], 'container-title': 'Cureus', 'original-title': [], 'language': 'en', 'link': [ { 'URL': 'https://www.cureus.com/articles/52299-proxalutamide-significantly-accelerates-viral-clearance-and-reduces-time-to-clinical-remission-in-patients-with-mild-to-moderate-covid-19-results-from-a-randomized-double-blinded-placebo-controlled-trial', 'content-type': 'unspecified', 'content-version': 'vor', 'intended-application': 'similarity-checking'}], 'deposited': { 'date-parts': [[2024, 2, 9]], 'date-time': '2024-02-09T19:34:20Z', 'timestamp': 1707507260000}, 'score': 1, 'resource': { 'primary': { 'URL': 'https://www.cureus.com/articles/52299-proxalutamide-significantly-accelerates-viral-clearance-and-reduces-time-to-clinical-remission-in-patients-with-mild-to-moderate-covid-19-results-from-a-randomized-double-blinded-placebo-controlled-trial'}}, 'subtitle': [], 'short-title': [], 'issued': {'date-parts': [[2021, 2, 22]]}, 'references-count': 14, 'URL': 'http://dx.doi.org/10.7759/cureus.13492', 'relation': {}, 'ISSN': ['2168-8184'], 'subject': [], 'published': {'date-parts': [[2021, 2, 22]]}}
Loading..
Please send us corrections, updates, or comments. c19early involves the extraction of 100,000+ datapoints from thousands of papers. Community updates help ensure high accuracy. Treatments and other interventions are complementary. All practical, effective, and safe means should be used based on risk/benefit analysis. No treatment or intervention is 100% available and effective for all current and future variants. We do not provide medical advice. Before taking any medication, consult a qualified physician who can provide personalized advice and details of risks and benefits based on your medical history and situation. FLCCC and WCH provide treatment protocols.
  or use drag and drop   
Submit